Article

ifa Systems acquires inoveon

ifa Systems AG has acquired inoveon Corp. ifa Systems provides ophthalmology-related software applications, including an electronic health record system that has been adopted in Europe and Latin America and now has been introduced into the North American and Asian markets. inoveon Corp. is a medical services company focused on managing diabetic eye disease, clinical research, and development.

Oklahoma City, OK-ifa Systems AG has acquired inoveon Corp.

ifa Systems provides ophthalmology-related software applications, including an electronic health record system that has been adopted in Europe and Latin America and now has been introduced into the North American and Asian markets. inoveon Corp. is a medical services company focused on managing diabetic eye disease, clinical research, and development.

The two companies previously have collaborated in developing open clinical and health information technology standards. The merger is expected to broaden ifa’s product line and distribution structure and further its international market share in 17 countries managing more than 70 million patients’ data.

The merger also means that Oklahoma City will become a hub for international telemedicine activities for inoveon, including service development and consulting activities. The inoveon platform will be extended, and its services will expand to include new ones for ifa’s installed client base.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.